Basel, North West Switzerland
Web: Novartis external link
Ort: Basel
Verwandt mit:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

Medizin 23.5
New analyses from the FLAME study suggest dual bronchodilator Ultibro Breezhaler provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil (a type of white blood cell)  counts -   Data was published in the centenary issue of the American Thoracic Society's 'American Journal of Respiratory and Critica
Medizin 19.5

Phase III trial, first-line treatment with Zykadia resulted in improved progression-free survival (PFS) over SOC chemotherapy with maintenance, including in patients with brain metastases Zykadia i

Medizin 17.5

Better Hearts Better Cities is a Novartis Foundation initiative to improve cardiovascular health in low-income urban communities by addressing the prevention, management and control of hypertension.

Medizin 4.5

Exclusive license for emricasan supports rapidly growing development portfolio in chronic liver diseases, including NASH -   Conatus has initiated the Phase IIb ENCORE-LF clinical trial with emricasan in NASH.

Medizin 18.5

Updated analyses from the Kisqali pivotal Phase III MONALEESA-2 trial in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer to be presen

Medizin 11.5

Community Partnership Day symbolizes the company's commitment to improving people's lives and serving our local communities -   Follow the excitement with #NovartisCPD2017 and #proudmoments2017 via

Medizin 28.4

Novartis receives FDA approval for Rydapt in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM) Approval in newly diagnosed FLT3-mutated AML rep